Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 7/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26634940 | 0.87 | DDB1 (0.51) | DRD2DDB1CRBNSIGMAR1 | |
| SCHEMBL25123194 | 0.85 | DDB1 (0.52) | DRD2DDB1CRBN | |
| SCHEMBL27197516 | 0.84 | LMNA (0.47) | DRD2DDB1CRBNDRD4 | |
| SCHEMBL24257354 | 0.83 | DRD2 (0.66) | DRD2DRD4SIGMAR1 | |
| SCHEMBL30908108 | 0.83 | DDB1 (0.55) | DRD2DDB1CRBN | |
| SCHEMBL30741773 | 0.82 | DRD2 (0.51) | DRD2DDB1CRBNDRD4SIGMAR1 | |
| SCHEMBL30289405 | 0.82 | DDB1 (0.54) | DRD2DDB1CRBNSIGMAR1 | |
| SCHEMBL30981012 | 0.81 | DDB1 (0.45) | DRD2DDB1CRBNDRD4 | |
| SCHEMBL23142741 | 0.79 | DDB1 (0.49) | DRD2DDB1CRBN | |
| SCHEMBL25035205 | 0.79 | KCNA3 (0.44) | DRD2DDB1CRBNSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124465-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2024-04-18 | — | — | US | disclosed |
| WO-2022133285-A1 | MOLECULES AND METHODS RELATED TO TREATMNET OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124465-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | JAK2, JAK1, JAK3 | DRD2 3059/4885DDB1 1696/4885CRBN 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.